The Timing Hypothesis: Hormone Therapy for Treating Symptomatic Women During Menopause and Its Relationship to Cardiovascular Disease

Mehta, Jaya; Chester, Rebecca; Kling, Juliana M.

doi:10.1089/jwh.2018.7201

Cited by 26 publications

(16 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…59-62 Subsequent research and analysis of the early data has shown that risks vary by dosage, regimen, and timing of initiation of HT, and that for most women the benefits outweigh the risks. 63-65 This is reflected in current guidelines and recommendations, which suggest that HCPs should feel confident in offering systemic HT to most women after an appropriate assessment, using an informed and shared decision-making process. 66,67…”

Section: Discussionmentioning

confidence: 99%

Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis

et al. 2019

View full text Add to dashboard Cite

This report uses data from 2015 and 2016 to examine the use of prescribed medicines by adults living in their own homes in England. It provides information on the number of prescribed medicines taken in the last week, and the proportion of the population taking specific classes of medicines, by sociodemographic and health factors. Key findings  In 2015/16 48% of adults had taken at least one prescribed medicine (not including contraception or nicotine replacement therapy) in the last week. This increased with age from 19% of young adults aged 16 to 24 to more than 90% of those aged 75 and over. The proportion of adults taking one or more prescribed medicines was similar to 2012/13.  In 2015/16, 24% of adults were taking three or more medicines.  The prevalence of prescribed medicine use was higher in more deprived areas: 54% of adults in the most deprived fifth of areas took at least one medicine, compared with 45% in the least deprived areas.  Prescribed medicine use was much higher than average among those with self-reported bad or very bad general health (85%), a limiting or non-limiting longstanding condition (76% and 71% respectively), or probable mental ill health (63%).  The most commonly used prescribed medicines were antihypertensives (by 15% of adults) and lipid-lowering medicines (14%); followed by proton-pump inhibitors for reducing acid in the stomach (11%); analgesics and non-steroidal anti-inflammatory drugs (11%); and antidepressants (10%).

show abstract

Section: Discussionmentioning

confidence: 99%

Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Unexpectedly, the WHI trial (which included women aged 50-79, mean age=63) showed an elevated risk of cardiovascular events in the oCEE + MPA treatment arm in all women (CHD HR =1.29, 95% CI 1.02 – 1.63, Stroke HR = 1.41, 95% CI 1.07-1.63) ( 24 ). Since 2002, WHI analyses stratified by age group, as well as observational studies and further RCTs including the Danish Osteoporosis Prevention Study (DOPS), KEEPS, ELITE have demonstrated that HT started in women <60 years or within 10 years of their final menstrual period (FMP) has neutral to beneficial effects on cardiovascular health (CVH) ( 20 , 34 , 35 , 44 ) ( Figure 1 )…”

Section: Benefits and Risks Of Menopause Hormone Therapy (Ht)mentioning

confidence: 99%

Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts

2021

Self Cite

View full text Add to dashboard Cite

Menopausal hormone therapy (HT) prescribing practices have evolved over the last few decades guided by the changing understanding of the treatment’s risks and benefits. Since the Women’s Health Initiative (WHI) trial results in 2002, including post-intervention analysis and cumulative 18-year follow up, it has become clear that the risks of HT are low for healthy women less than age 60 or within ten years from menopause. For those who are experiencing bothersome vasomotor symptoms, the benefits are likely to outweigh the risks in view of HT’s efficacy for symptom management. HT also has a role in preventing osteoporosis in appropriate candidates for treatment. A comprehensive overview of the types, routes, and formulations of currently available HT, as well as HT’s benefits and risks by outcomes of interest are provided to facilitate clinical decision making.

show abstract

“…The decision to initiate or continue MHT involves a careful assessment (11,12) and women´s choice. This decision can be supported by tools that could help identify the appropriate women for MHT or for others therapeutic alternatives (13,14).…”

Section: Introductionmentioning

confidence: 99%

Women with low quality of life by cervantes-short form scale choose menopausal hormone therapy

Fasero

Hernández

Varillas‐Delgado

et al. 2020

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

The Timing Hypothesis: Hormone Therapy for Treating Symptomatic Women During Menopause and Its Relationship to Cardiovascular Disease

Cited by 26 publications

References 37 publications

Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis

Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis

Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts

Women with low quality of life by cervantes-short form scale choose menopausal hormone therapy

Contact Info

Product

Resources

About